国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Chinese clinical trial shows breakthrough in liver cancer survival

By ZHOU WENTING in Shanghai | chinadaily.com.cn | Updated: 2026-03-05 21:29
Share
Share - WeChat
Doctors from Shanghai-based Zhongshan Hospital, affiliated with Fudan University, brief the media on Thursday on the results of a multicenter clinical study showing that an innovative neoadjuvant treatment for intrahepatic cholangiocarcinoma, a common malignant liver tumor, can significantly extend patient survival. [Photo provided to chinadaily.com.cn]

A pioneering Chinese study has found that a new drug cocktail administered before surgery can nearly double the time patients with a deadly form of liver cancer live without the disease returning.

The study, published Thursday in the New England Journal of Medicine, focused on intrahepatic cholangiocarcinoma, or ICC. This cancer forms in the bile ducts inside the liver and is notorious for being "silent," often discovered only after it has reached an advanced stage.

Led by Zhongshan Hospital, affiliated with Fudan University, the trial involved 11 hospitals across China. Experts say the findings offer a new "standard of care" for a disease where the five-year survival rate after surgery is currently only 25 percent to 40 percent.

The researchers tested a neoadjuvant protocol, which is a treatment given as a first step to shrink a tumor before the main surgery. In this trial, 178 patients with a median age of 59 were recruited by February 2025. One group received three cycles of Gemox chemotherapy along with a targeted therapy drug and an immunotherapy drug, which helps the body's own immune system recognize and attack cancer cells. The other group underwent immediate surgery, which is the traditional standard practice.

The results showed that the drug combination significantly delayed the return of the cancer. The median event-free survival — the length of time after treatment that a patient remains free of specific complications or cancer recurrence — was 18 months for those who received the drug cocktail. In contrast, the group that went straight to surgery saw a median of only 8.7 months.

Shi Guoming, one of the lead researchers, noted that the tumors in the drug-treatment group significantly shrank, with an objective response rate of 55 percent. This term refers to the percentage of patients whose tumors partially or completely disappeared during the treatment phase.

China is disproportionately affected by this disease, seeing over 50,000 new cases annually, which accounts for more than half of the global total. The study, which began in 2021, also showed a promising trend in overall survival. The 24-month survival rate for the drug-protocol group was 79 percent, compared to 61 percent for the surgery-only group.

Zhou Jian, president of Zhongshan Hospital, said that as the study progresses, it may further demonstrate long-term benefits for patients. The team presented preliminary results at the annual meeting of the European Society for Medical Oncology in Germany in October 2025, where it garnered international attention. Shi expressed hope that the findings will be further validated through international studies so the Chinese protocol can eventually be used as a global cure.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
桃园市| 乌拉特后旗| 香港 | 江北区| 丁青县| 峨眉山市| 长沙县| 梨树县| 子洲县| 安顺市| 滨海县| 惠水县| 敦化市| 加查县| 依兰县| 开平市| 军事| 泰宁县| 洛浦县| 青冈县| 通江县| 木兰县| 平顶山市| 堆龙德庆县| 金溪县| 天柱县| 泾源县| 台安县| 贵溪市| 南部县| 南皮县| 武夷山市| 湖南省| 宜宾县| 佛坪县| 石家庄市| 宁化县| 安阳市| 荣昌县| 资中县| 吉隆县|